TITLE

Bendamustine hydrochloride receives FDA approval

AUTHOR(S)
Rai, Kanti R.
PUB. DATE
April 2008
SOURCE
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p21
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on a 2008 approval by the U.S. Food and Drug Administration of bendamustine hydrochloride injection for the treatment of chronic lymphocytic leukemia patients. The data that supported the approval reportedly showed that patients treated with bendamustine hydrochloride had better clinical outcomes than those treated with chlorambucil. The common adverse events like myelosuppression and fever are noted.
ACCESSION #
31705850

 

Related Articles

  • IMBRUVICA APPROVED FOR PREVIOUSLY TREATED PATIENTS.  // Biotech Business;Mar2014, Vol. 27 Issue 3, p6 

    The article on the approval from the U.S. Food and Drug Administration (FDA) received by Biologics for IMBRUVICA (ibrutinib) to treat chronic lymphocytic leukemia (CLL) patients who have received at least one prior therapy. The drug has been approved originally to treat patients with mantle cell...

  • United States : IMBRUVICA (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p.  // TendersInfo News;7/30/2014, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on the supplemental new drug application Imbruvica capsules for treatment of chronic lymphocytic leukemia.

  • Arzerra.  // Pharmaceutical Representative;Dec2009, Vol. 39 Issue 12, p11 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the drug Arzerra for the treatment of patients with chronic lymphocytic leukemia (CLL). Arzerra has been approved to CLL patients who have cancer that is no longer controlled by other forms of chemotherapy....

  • FDA: Complete Response for Rituxan in CLL.  // Bioworld Week;11/23/2009, Vol. 17 Issue 47, p5 

    The article reports on the status of biopharmaceutical firms Genetech Inc. and Biogen Idec Inc.'s drug application approval for Rituxan to treat chronic lymphocytic leukemia (CLL) in the U.S. It mentions that the Food and Drug Administration (FDA) has delayed its decision to approve the drug due...

  • Genmab Gets Accelerated OK for Arzerra in Refractory CLL. Sheridan, Cormac // BioWorld Today;10/28/2009, Vol. 20 Issue 208, p1 

    The article reports on the accelerated drug approval granted by the U.S. Food and Drug Administration (FDA) to ofatumumab (Arzerra), a drug for patients with chronic lymphocytic leukemia (CLL) developed by Genmab of Copenhagen, Denmark. GlaxoSmithKline plc, Genmab's development partner for the...

  • GSK and Genmab win FDA accelerated approval for leukemia drug.  // PharmaWatch: Cancer;Dec2009, Vol. 8 Issue 12, p14 

    The article presents information on the U.S. Food & Drug Administration's (FDA) approval of chronic lymphocytic leukemia drug Arzerra developed jointly by GlaxoSmithKline and Genmab Inc. The approval came after the positive recommendation from the FDA's Oncologic Drugs Advisory Committee....

  • Treanda approved for chronic lymphocytic leukemia. Traynor, Kate // American Journal of Health-System Pharmacy;5/1/2008, Vol. 65 Issue 9, p793 

    The article reports the approval of bendamustine hydrochloride for injection by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia. It relates that the drug developed by Cephalon Inc. will be marketed in the country as Treanda. It mentions that the...

  • New drugs: Ciclesonide, certolizumab pegol, and bendamustine hydrochloride. Hussar, Daniel A. // Journal of the American Pharmacists Association: JAPhA;Jul/Aug2008, Vol. 48 Issue 4, p557 

    The article provides information on several drugs approved for marketing by the U.S. Food and Drug Administration. It includes the corticosteroid Ciclesonide for the treatment of nasal symptoms associated with seasonal allergic rhinitis, Certolizumab pegol, a tumor necrosis factor (TNF) blocker...

  • Little evidence of Weber effect in US FAERS.  // Reactions Weekly;Apr2014, Vol. 1498 Issue 1, p3 

    An abstract of the article "The Weber Effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010," by K. B. Hoffman and colleagues is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics